{"SPADE_UN_21704": {"Sequence Information": {"Peptide Name": "FLAKO6 AMD", "Sequence": "FALALKALKKLKKALKKAL", "Sequence Length": 19, "Biological Activity": ["Anti-Gram+", "Anti-Gram-", "Anticancer", "Antifungal", "Anti-Mammalian Cell"], "Binding Target": "1. Lipid Bilayer", "Source": "", "Gene": "", "PDB ID": "", "UniProt Entry": [], "Literature": [{"Title": "Designing Anticancer Peptides by Constructive Machine Learning.", "Pubmed ID": "29679519", "Reference": "ChemMedChem. 2018;13:1300-1302", "Author": "Grisoni F, Neuhaus CS, Gabernet G, Müller AT, Hiss JA, Schneider G", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/29679519"}, {"Title": "Short bioactive peptides", "Pubmed ID": "", "Reference": "PATENT US 6875744B2. 2005;:", "Author": "Owen DR, Kenner LA", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/"}], "Mass": 2096.73, "PI": 10.78, "Net Charge": 7, "Hydrophobicity": 0.38, "Frequent Amino Acids": "KLA", "Absent Amino Acids": "CDEGHIMNOPQRSTUVWY", "Basic Residues": 7, "Acidic Residues": 0, "Hydrophobic Residues": 12, "Polar Residues": 7, "Positive Residues": 7, "Negative Residues": 0, "SPADE ID": "SPADE_UN_21704", "Similar Sequences": [{"SPADE_ID": "SPADE_N_06698", "Similarity": 1.0, "Sequence": "FALALKA"}, {"SPADE_ID": "SPADE_N_06699", "Similarity": 1.0, "Sequence": "FALALKAKKL"}, {"SPADE_ID": "SPADE_N_06700", "Similarity": 1.0, "Sequence": "FALALKALKK"}], "Hemolytic Activity": "Human erythrocytes:50% Hemolysis=62.3 µM,Human fibroblasts WI-38:EC50=18.2 µM,Human leukocytes:LD50=78 µg/ml", "Target Organism": "Human breast adenocarcinoma MCF-7(EC50=7µM),Staphylococcus aureus ATCC 6538(MIC=10µg/ml),Pseudomonas aeruginosa ATCC 9027(MIC=10µg/ml),Saccharomyces cerevisiae(MFC=25µg/ml),Escherichia coli ATCC 25922(MBC=10µg/ml),Pseudomonas aeruginosa ATCC 27853(MBC=8µg/ml),Staphylococcus aureus ATCC 25923(MBC=8µg/ml),Candida albicans ATCC 10231(MFC=>50µg/ml),Human colon adenocarcinoma SW480(LD50=26µg/ml),Human melanoma BMKC(LD50=44µg/ml),Human lung carcinoma H1299(LD50=16µg/ml),Human cervical carcinoma HeLa S3(LD50=25µg/ml),Human prostate adenocarcinoma PC-3(LD50=8µg/ml)"}}}